HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2013-11-07Clinical Trial Update: Rifaximin as a Modulator of Microbial Translocation and Immune Activation [Phase 2]
Phase 2 clinical trial evaluating rifaximin as a modulator of microbial translocation and immune activation in HIV-1 infection has completed…
-
CLINICAL_TRIALS trial_result · 2013-11-06Clinical Trial Update: Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects [Phase 3]
Phase 3 study comparing darunavir/ritonavir plus tenofovir/emtricitabine versus darunavir/ritonavir plus raltegravir in antiretroviral-naïve…
-
CLINICAL_TRIALS trial_result · 2013-11-05Clinical Trial Update: Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options [Phase 3]
Phase 3 safety study assessing tipranavir co-administered with low-dose ritonavir in adults with advanced HIV-1 infection and limited treatm…
-
CLINICAL_TRIALS trial_result · 2013-11-04Clinical Trial Update: Effectiveness of a Community-level HIV/STD Prevention Intervention in Promoting Safer Sexual Behaviors in High-risk Populations [Phase 3]
Phase 3 trial evaluating a community-level intervention aimed at promoting safer sexual behaviors to reduce HIV and sexually transmitted inf…
-
CLINICAL_TRIALS trial_result · 2013-11-01Clinical Trial Update: Quality of Life and Changes in Metabolism of Lipids and Glucose After Switching to a Nevirapine-based Regimen in HIV+ Patients [Phase 4]
This Phase 4 trial evaluated quality of life and metabolic changes in HIV-infected patients after switching to a nevirapine-based antiretrov…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-11-01Clinical Trial Update: A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients. [Phase 2]
A Phase 2 randomized trial comparing tipranavir boosted with ritonavir to lopinavir boosted with ritonavir, each with background antiretrovi…
-
FDA approval · 2013-10-31FDA Approved: PREZISTA — Supplemental Application (Janssen Products LP)
The FDA approved a supplemental application for Prezista (darunavir) submitted by Janssen Products LP.
-
CLINICAL_TRIALS trial_result · 2013-10-31Clinical Trial Update: The Effect of Intermittent Rifampicin on Raltegravir [Phase 1]
A Phase 1 study assessed how intermittent rifampicin affects raltegravir exposure, in participants with HIV and tuberculosis. The trial has …
-
CLINICAL_TRIALS trial_result · 2013-10-30Clinical Trial Update: A Phase 2 Study Of PF-00232798 In HIV Positive Patients [Phase 2]
Pfizer completed a Phase 2 trial of PF-00232798 in HIV-infected patients, with results posted in 2013.
-
CLINICAL_TRIALS trial_result · 2013-10-30Clinical Trial Update: Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults [Phase 2]
Phase IIa dose-ranging study of GSK1349572 (dolutegravir) in HIV-1 infected adults completed; results posted in 2013.
-
CLINICAL_TRIALS research · 2013-10-30Clinical Trial Update: Biomarkers of Protocol Compliance and Product Adherence
The document provides an update on a completed clinical trial investigating biomarkers of protocol compliance and product adherence in HIV p…
-
CLINICAL_TRIALS trial_result · 2013-10-29Clinical Trial Update: Rwanda Selenium Supplementation Clinical Trial [Phase 3]
A Phase 3 clinical trial in Rwanda evaluating selenium supplementation for HIV has completed. The study was sponsored by The Canadian Colleg…
-
CLINICAL_TRIALS trial_result · 2013-10-28Clinical Trial Update: A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines [Phase 2]
A Phase 2 clinical trial update for TMC278 (rilpivirine) in HIV-1 infected patients who have not received antiretroviral therapy, with resul…
-
CLINICAL_TRIALS trial_result · 2013-10-28Clinical Trial Update: Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy [Phase 4]
Phase 4 pharmacokinetic study assessing the tablet formulation of lopinavir/ritonavir at standard and increased dosages during pregnancy; th…
-
CLINICAL_TRIALS trial_result · 2013-10-28Clinical Trial Update: KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18) [Phase 2, Phase 3]
Completed phase 2/3 trial comparing once-daily versus twice-daily lopinavir/ritonavir tablets dosed by weight in HIV-1 infected children (PE…
-
CLINICAL_TRIALS trial_result · 2013-10-25Clinical Trial Update: Randomized Control Trial Copper Intrauterine Device and Depo-medroxyprogesterone Acetate (DMPA) of HIV+ Women in Malawi [NA]
A completed randomized trial compared a copper intrauterine device with Depo-medroxyprogesterone acetate for contraception in HIV-positive w…
-
FDA approval · 2013-10-24FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for Isentress (raltegravir) from Merck Sharp & Dohme LLC.
-
CLINICAL_TRIALS trial_result · 2013-10-24Clinical Trial Update: Establishing Effectiveness of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria in Pregnancy [Phase 3]
A Phase 3 trial evaluated daily co-trimoxazole prophylaxis for preventing malaria in pregnancy, including HIV-infected women. The study has …
-
FDA approval · 2013-10-24FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Isentress (raltegravir) submitted by Merck Sharp & Dohme LLC.
-
CLINICAL_TRIALS trial_result · 2013-10-24Clinical Trial Update: Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients [Phase 4]
Phase 4 trial examining whether switching from efavirenz to raltegravir affects vascular function and bone markers in HIV-infected patients;…
-
FDA approval · 2013-10-23FDA Approved: TRUVADA — Supplemental Application (Gilead Sciences, Inc)
The FDA approved a supplemental application for Truvada (emtricitabine and tenofovir disoproxil fumarate) submitted by Gilead Sciences, Inc.
-
FDA approval · 2013-10-23FDA Approved: COMPLERA — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for COMPLERA submitted by Gilead Sciences, related to the existing HIV-1 therapy regimen.
-
FDA approval · 2013-10-23FDA Approved: STRIBILD — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for STRIBILD (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) from Gilea…
-
CLINICAL_TRIALS trial_result · 2013-10-22Clinical Trial Update: Growth Hormone in the Treatment of HIV-Associated Wasting [Phase 3]
Phase 3 trial evaluating recombinant human growth hormone for HIV-associated wasting has completed. The sponsor was EMD Serono.
-
CLINICAL_TRIALS trial_result · 2013-10-22Clinical Trial Update: Kaletra Sex/Gender Pharmacokinetics (PK) Study [Phase 4]
Phase 4 pharmacokinetic study evaluating sex/gender differences in Kaletra (lopinavir/ritonavir) for HIV infection; results posted in 2013.